

4. On information and belief, Defendant Sandoz Inc. (“Sandoz”) is a corporation organized and existing under the laws of the State of Colorado, having a principal place of business at 506 Carnegie Center, Suite 400, Princeton, New Jersey 08540.

JURISDICTION AND VENUE

5. This action arises under the patent laws of the United States of America. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

6. On information and belief, Sandoz manufactures, distributes and sells generic pharmaceutical products throughout the United States, including in the State of Delaware.

7. This Court has personal jurisdiction over Sandoz because Sandoz has purposefully availed itself of the privilege of doing business in the State of Delaware so as to reasonably allow jurisdiction to be exercised over it. Sandoz also has agreed not to contest personal jurisdiction in Delaware in connection with this matter.

8. Venue is proper in this judicial district pursuant to 28 U.S.C. §§ 1391(b) and (c), and 28 U.S.C. § 1400(b).

CLAIM FOR RELIEF

9. Genzyme holds approved New Drug Application (“NDA”) No. 021-027 for Hectorol® injectable (2 µg/mL), which product contains the active ingredient doxercalciferol.

10. Hectorol® injectable was approved by the U.S. Food and Drug Administration (“FDA”) on April 6, 2000, and is currently indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

11. On information and belief, Sandoz submitted to the FDA Abbreviated New Drug Application (“ANDA”) No. 91-333 under 21 U.S.C. § 355(j) seeking approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation into the United States of a generic product containing 2 µg/mL doxercalciferol (“Sandoz’s Proposed Generic Product”).

Infringement Of The ‘116 Patent

12. Plaintiffs repeat and reallege the allegations of paragraphs 1-11 as though fully set forth herein.

13. On February 11, 1997, United States Patent No. 5,602,116 (“‘116 patent”), titled “Method For Treating And Preventing Secondary Hyperparathyroidism” was duly and legally issued by the United States Patent and Trademark Office. The ‘116 patent claims a method for lowering or maintaining lowered serum parathyroid hormone in human patients suffering from hyperparathyroidism secondary to end stage renal disease by administering doxercalciferol. A copy of the ‘116 patent is attached hereto as Exhibit A.

14. Bone Care is the owner of the ‘116 patent. Genzyme is the sole member of Bone Care.

15. On information and belief, Sandoz submitted its ANDA to the FDA for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation into the United States of Sandoz’s Proposed Generic Product prior to the expiration of the ‘116 patent.

16. By submitting ANDA No. 91-333 to the FDA for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation into the United States of Sandoz’s Proposed Generic Product prior to the expiration of the ‘116 patent, Sandoz has infringed the ‘116 patent under 35 U.S.C. § 271(e)(2)(A).

17. On information and belief, the commercial manufacture, use, sale, offer for sale and/or importation of Sandoz's Proposed Generic Product, if approved by the FDA, would infringe one or more claims of the '116 patent under 35 U.S.C. § 271.

18. On information and belief, the sale or offer for sale of Sandoz's Proposed Generic Product, if approved by the FDA, would induce infringement of, and/or be contributory infringement of, one or more claims of the '116 patent under 35 U.S.C. § 271.

19. Plaintiffs are entitled to the relief provided by 35 U.S.C. §271(e)(4), including an order of this Court that the effective date of any approval of ANDA No. 91-333 be a date which is not earlier than the expiration of the '116 patent, and any other exclusivity to which Genzyme and/or Bone Care are or become entitled.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully request the following relief:

A. A Judgment declaring that Sandoz has infringed one or more claims of the '116 patent by filing its ANDA No. 91-333;

B. An Order that the effective date of any FDA approval of Sandoz's ANDA No. 91-333 be no earlier than the date on which the '116 patent expires, and any other exclusivity to which Genzyme and/or Bone Care are or become entitled;

C. Preliminary and permanent injunctions enjoining Sandoz, its officers, agents, attorneys and employees, and those acting in privity or concert with it, from engaging in the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Sandoz's Proposed Generic Product until after the expiration of the '116 patent, and any other exclusivity to which Genzyme and/or Bone Care are or become entitled;

D. If Sandoz engages in the commercial manufacture, use, offer to sell or sale within the United States or importation into the United States of Sandoz's Proposed Generic

Product prior to the expiration of the '116 patent, and any other exclusivity to which Genzyme and/or Bone Care are or become entitled, a Judgment awarding damages to Plaintiffs resulting from such infringement;

- E. The costs and reasonable attorney fees of Plaintiffs in this action; and
- F. Such further and other relief as this Court may deem just and proper.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

Karen Jacobs Louden

Jack B. Blumenfeld (#1014)

Karen Jacobs Louden (#2881)

1201 North Market Street

P.O. Box 1347

Wilmington, DE 19899

(302) 658-9200

jblumenfeld@mnat.com

klouden@mnat.com

Attorneys for Plaintiffs Bone Care

International LLC and Genzyme Corporation

OF COUNSEL

Robert L. Baechtold

Scott K. Reed

Filko Prugo

Christopher E. Loh

Fiona E. Darkin

Daniel Minion

FITZPATRICK CELLA HARPER &
SCINTO

30 Rockefeller Plaza

New York, New York 10112-3800

(212) 218-2100

July 16, 2009